The results paved the way for liraglutide, branded as Saxenda, to be approved in the US as a once-a-day subcutaneous injection in December 2014 and in Europe in 2015 for the treatment of chronic weight management combined with a reduced calorie diet and increased physical exercise (Molteni, Chen)
It says those combinations require immediate medical evaluation because they can signal gastroparesis or bowel obstruction, which it calls rare but serious complications needing imaging and assessment beyond self-management
This is a high bar
XPG Xtreme Performance Gels L-Carnitine Gel 3.4 oz Highlights & Benefits
In the human studies FDA identified covering rectal, intra-articular, intravesical, and intravenous administration no serious adverse events were reported, and the most common side effects were headache and flatulence at rates comparable to placebo
Nausea affects 28% at the 12mg dose